Stockreport

Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy

Clovis Oncology, Inc.  (CLVS) 
Last clovis oncology, inc. earnings: 2/24 04:05 pm Check Earnings Report
PDF Rubraca® (rucaparib) offers a new monotherapy maintenance treatment option for eligible women with relapsed, platinum-sensitive ovarian cancer, who harbor either a BRCA1 [Read more]